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Letters to the EditorThe data by Drs Shingu and Matsui
suggest the utility and need for proce-
dures to address subvalvular tethering
in patients with ischemic MR. Cur-
rently reported surgical procedures to
address subvalvular tethering are
conceptually reasonable and heteroge-
nous.3-5 A tailored and heterogeneous
approach based on preoperative 3-
dimensional evaluation of mitral valve
geometry seems necessary to address
patients’ variability. Standardization is
also necessary to perform subvalvular
procedures in many institutions. This
bidirectional improvement in therapeu-
tic approach is required to achieve a fa-
vorable outcome in affected patients.
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CYCLOPHOSPHAMIDE ON
MYOCARDIAL ISCHEMIA/
REPERFUSION INJURY IN RATS
To the Editor:
Wang and associates1 have recently
published a very interesting and in-
novative origin of thought in which
investigators have demonstrated the
protective role of cyclophosphamide
against myocardial ischemia/reperfu-
sion injury in rats. In this study, cyclo-
phosphamide showed a favorable
effect on myocardial function in vari-
ous parameters, which included im-
provement in left ventricular systolic
pressure, left ventricular end-diastolic
pressure, and maximum rate of rise or
fall of left ventricular pressure. Apart
from this, infarct size was reduced,
along with improvement in histopatho-
logic damage score, and plasma high-
sensitivity C-reactive protein concen-
tration, which is an inflammatory
marker, was reduced significantly.
However, we would like to highlight
some of the points regarding this study
1. The study showed that cyclophos-
phamide decreased the C-reactive
protein levels significantly, but it
is not the proposed specific mecha-
nism of action alone to have
anti-inflammatory action. Other
markers of inflammation, such as
Cox inhibition, should also have
been evaluated before making the
final conclusion.
2. In this study, pretreatment with
cyclophosphamide or saline was
given before inducing ischemia/re-
perfusion. Thus, in this study de-
sign, investigators should have
evaluated whether the drug cyclo-
phosphamide or saline had any
beneficial or detrimental effect be-
fore proceeding for ischemia and
reperfusion or sham surgery.
3. The cardioprotective role of cyclo-
phosphamide could have been
evaluated on creatine kinase, myo-
cardial band of creatine kinase,
and tropinin I, which are the myo-
cardial injury markers.2,3of Thoracic and Cardiovascular Surge4. Various studies have evaluated the
role of cytokines, which include
interleukins 6 and 8, interferon-
gamma, and tumor necrosis factor-
a, which are upregulated after ische-
mia/reperfusion injury.4,5 In this
present study, too, the expression
of these cytokines, which are medi-
ators of inflammation, could have
been evaluated in comparison with
saline or cyclophosphamide.
The present study provides useful
information for more effective and
targeted treatment for patients with
ischemic heart disease, but the afore-
mentioned points should be discussed
for future therapeutic implication and
reconfirmation in clinical studies.
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